Clinical trials: CD20 Positive
Non-Hodgkin's Lymphoma
A Study of YM155 Plus Rituximab in Subjects With Non-Hodgkin's Lymphoma Who Have Received Prior Treatment
The purpose of this study is to evaluate response rate, survival, safety and tolerability of YM155 given in combination with rituximab in subjects with Non-Hodgkin's Lymphoma.
- Trial name
- NCT01007292
- Testing
- YM155, Rituximab
- Where
- 19 sites in United States, France and 2 more
- Volunteers
- 43 people
- Sponsor
- Astellas Pharma Inc
Lymphoma, Non-Hodgkin
Study to Assess if ABP798 is Safe & Effective in Treating Non Hodgkin Lymphoma Compared to Rituximab
This was a randomized, double-blind, active-controlled, multiple-dose, clinical similarity study to evaluate the efficacy, pharmacokinetics, pharmacodynamics, safety, tolerability and immunogenicity of ABP 798 compared with…
- Trial name
- JASMINE (NCT02747043)
- Testing
- ABP 798, Rituximab
- Where
- 98 sites in United States, Australia and 18 more
- Volunteers
- 256 people
- Sponsor
- Amgen
Ann Arbor Stage III Grade 1 Follicular Lymphoma, Ann Arbor Stage III Grade 2 Follicular Lymphoma
Acalabrutinib, Lenalidomide, and Rituximab for the Treatment of CD20 Positive Stage III-IV, Grade 1-3a Follicular Lymphoma
This phase II trial studies how well acalabrutinib, lenalidomide, and rituximab work in treating patients with CD20 positive stage III-IV, grade 1-3a follicular lymphoma.
- Conditions
- Ann Arbor Stage III Grade 1 Follicular Lymphoma, Ann Arbor Stage III Grade 2 Follicular Lymphoma, Ann Arbor Stage III Grade 3 Follicular Lymphoma, Ann Arbor Stage IV Grade 1 Follicular Lymphoma
- Trial name
- NCT04404088
- Testing
- Acalabrutinib, Lenalidomide, Rituximab
- Where
- United States
- Volunteers
- 80 people
- Sponsor
- M.D. Anderson Cancer Center
B-cell Non-Hodgkins Lymphoma, Chronic Lymphocytic Leukemia
Study to Evaluate Safety and Tolerability of XmAb13676 (Plamotamab) in Patients With CD20-expressing Hematologic Malignancies
The purpose of this study is to determine the safety and tolerability of intravenous (IV) and subcutaneous (SC) administration of XmAb13676 and to determine the maximally tolerated dose (MTD) and/or recommended dose (RD).
- Trial name
- NCT02924402
- Testing
- XmAb13676
- Where
- 23 sites in United States, France and 2 more
- Volunteers
- 154 people
- Sponsor
- Xencor, Inc.
Contiguous Stage II Grade 1 Follicular Lymphoma, Contiguous Stage II Grade 2 Follicular Lymphoma
Pegfilgrastim and Rituximab in Treating Patients With Untreated, Relapsed, or Refractory Follicular Lymphoma, Small Lymphocytic Lymphoma, or Marginal Zone Lymphoma
This phase II trial studies the side effects and how well giving pegfilgrastim together with rituximab works in treating patients with untreated, relapsed, or refractory follicular lymphoma, small lymphocytic lymphoma (SLL), or…
- Conditions
- Contiguous Stage II Grade 1 Follicular Lymphoma, Contiguous Stage II Grade 2 Follicular Lymphoma, Contiguous Stage II Grade 3 Follicular Lymphoma, Contiguous Stage II Marginal Zone Lymphoma
- Trial name
- NCT01682044
- Testing
- pegfilgrastim, rituximab, flow cytometry
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Roswell Park Cancer Institute
Follicular Lymphoma
Compare Efficacy, Safety, and Immunogenicity of Proposed Rituximab Biosimilar (DRL_RI) With MabThera® in LTB Follicular Lymphoma
The primary objective of the current study is to demonstrate the equivalent efficacy of rituximab (DRL_RI) and MabThera® in subjects with Low Tumor Burden Follicular Lymphoma (LTB-FL).
- Trial name
- FLINTER (NCT03976102)
- Testing
- DRL_RI (Proposed rituximab biosimilar), MabThera®
- Where
- 4 sites in United States
- Volunteers
- 317 people
- Sponsor
- Dr. Reddy's Laboratories Limited
Follicular Lymphoma
Study of MK-8808 for Participants With Follicular Lymphoma (MK-8808-001)
This study will evaluate the safety, pharmacokinetics, and anti-tumor activity of MK-8808 in combination with cyclophosphamide, vincristine, and prednisolone (CVP), and as a single agent, for participants with B-lymphocyte…
- Trial name
- NCT01370694
- Testing
- MK-8808, cyclophosphamide, vincristine
- Volunteers
- 7 people
- Sponsor
- Merck Sharp & Dohme LLC
Advanced Malignancies
Phase I/II Clinical Study of 1A46 Drug Substance
A phase I/II, first in human, single arm, open label study to evaluate the safety and efficacy of the injection of triple-specific T-cell engager 1A46 in adult subjects with R/R CD20 positive and/or CD19 positive B cell…
- Trial name
- NCT05987605
- Testing
- 1A46 Drug Substance
- Where
- China
- Volunteers
- 4 people
- Sponsor
- BioRay Pharmaceutical Co., Ltd.
Follicular Non-Hodgkin's Lymphoma, Nodal Marginal Zone Lymphoma
Safety and Efficacy Study of BCD-020 in Therapy of Indolent Non-Hodgkin's Lymphoma
This international multi-center, randomized, controlled, open-label study investigated the pharmacokinetics, pharmacodynamics, efficacy and safety of BCD-020 (INN: rituximab, CJSC Biocad) versus MabThera® (INN: rituximab, F.
- Conditions
- Follicular Non-Hodgkin's Lymphoma, Nodal Marginal Zone Lymphoma, Splenic Marginal Zone Lymphoma
- Trial name
- NCT01701232
- Testing
- rituximab
- Where
- 62 sites in Colombia, India and 3 more
- Volunteers
- 174 people
- Sponsor
- Biocad
Malignant Lymphoma
Phase 1/2 Study of the Combination of Pixantrone, Etoposide, Bendamustine and, in CD20 Positive Tumors, Rituximab in Patients With Relapsed Aggressive Non-Hodgkin Lymphomas of B- or T-cell Phenotype - the P[R]EBEN Study
This is a phase 1/2 open label study to assess the safety and efficacy of pixantrone in combination with bendamustine, etoposide and , for CD20 positive B-cell lymphomas, rituximab (P[R]EBEN), in patients with relapsed aNHL of B…
- Trial name
- NCT02678299
- Testing
- PREBEN
- Where
- 18 sites in Denmark, Finland and 3 more
- Volunteers
- 60 people
- Sponsor
- University of Aarhus
Indolent B-cell Non-Hodgkin's Lymphoma
GP2013 in Japanese Patients With CD20 Positive Low Tumor Burden Indolent B-cell Non-Hodgkin's Lymphoma
The purpose of this study is to evaluate safety and pharmacokinetic of GP2013 in Japanese patients with CD20 positive low tumor burden indolent B-cell NHL under weekly dosing schedule.
- Trial name
- NCT01933516
- Testing
- GP2013
- Where
- Japan
- Volunteers
- 6 people
- Sponsor
- Sandoz
Aggressive Non-Hodgkin Lymphoma, B-Cell Non-Hodgkin Lymphoma
Nivolumab and Combination Chemotherapy in Treating Participants With Diffuse Large B-Cell Lymphoma
This phase I/II trial studies the side effects and best dose of nivolumab and how well it works when giving together with combination chemotherapy in treating participants with diffuse large B-cell lymphoma.
- Conditions
- Aggressive Non-Hodgkin Lymphoma, B-Cell Non-Hodgkin Lymphoma, CD20 Positive, Diffuse Large B-Cell Lymphoma Unclassifiable
- Trial name
- NCT03704714
- Testing
- Cyclophosphamide, Doxorubicin Hydrochloride, Nivolumab
- Where
- 4 sites in United States
- Volunteers
- 30 people
- Sponsor
- Northwestern University
ALL (Acute B-Lymphoblastic Leukemia)
A Clinical Study Exploring the Safety, Efficacy and Cell Metabolic Kinetics of Universal Car-t Cell Injection in CD19 and / or CD20 Positive Relapsed / Refractory B-cell Acute Lymphoblastic Leukemia in Adolescents, Children and Adults
This study is a single arm, open label, dose exploring clinical trial to evaluate the safety, efficacy, cellular metabolic dynamics, and pharmacodynamics of ct1190b cells in relapsed / refractory B-cell acute lymphoblastic…
- Trial name
- NCT07470073
- Testing
- CT1190B cell injection
- Where
- China
- Volunteers
- 18 people
- Sponsor
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Diffuse Large B-Cell Lymphoma
A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA)
This open-label, randomized, parallel group study will evaluate the efficacy and safety of obinutuzumab in combination with cyclophosphamide, doxorubicin, vincristine, and prednisolone or prednisone (CHOP) chemotherapy versus…
- Trial name
- NCT01287741
- Testing
- Rituximab, Obinutuzumab, Cyclophosphamide
- Where
- 235 sites in United States, Argentina and 27 more
- Volunteers
- 1,418 people
- Sponsor
- Hoffmann-La Roche
B-cell Lymphoma, Chronic Lymphocytic Leukaemia
BI-1206 and an Anti-CD20 Antibody in Patients With CD32b Positive B-cell Lymphoma or Leukaemia
The purpose of this trial is to identify the tolerable dose of BI-1206 (both alone and in combination) for patients with B-cell lymphoma and leukaemia and further evaluate BI-1206 alone and in combination with an anti-CD20…
- Conditions
- B-cell Lymphoma, Chronic Lymphocytic Leukaemia, Waldenström Macroglobulinemia
- Trial name
- NCT02933320
- Testing
- BI-1206 single agent dose escalation phase, Combination of BI-1206 with rituximab escalation phase, BI-1206 single agent expansion phase
- Where
- 5 sites in United Kingdom
- Volunteers
- 14 people
- Sponsor
- Cancer Research UK
CD20 Positive B Cell Non-Hodgkin's Lymphoma
B001 in Patients With CD20 Positive B-cell Non Hodgkin's Lymphoma
It's the first-in-human study of Recombinant Humanized Anti-CD20 Monoclonal Antibody for Injection (B001). The main purpose of this study is to explore the safety and tolerance of B001 for patients with CD20 positive B-cell non…
- Trial name
- NCT03332121
- Testing
- B001
- Where
- 2 sites in China
- Volunteers
- 30 people
- Sponsor
- Shanghai Pharmaceuticals Holding Co., Ltd
CD20-positive B-cell Non-Hodgkin Lymphoma
A Phase 1 Study of TRS005 in Patients With R/R CD20-positive B-NHL.
This trial is a multicenter, open, single arm, dose increasing and extended clinical trial. The dose was increased according to the "3 + 3" rule.
- Trial name
- NCT05395533
- Testing
- Recombinant CD20 monoclonal antibody-MMAE conjugte for injection
- Where
- 6 sites in China
- Volunteers
- 147 people
- Sponsor
- Zhejiang Teruisi Pharmaceutical Inc.
Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma, Non-Hodgkin's Lymphoma
MB-CART20.1 Lymphoma
This trial is a phase I/II trial to assess safety, dose finding and feasibility of ex vivo generated MB-CART20.1 cells in patients with relapsed or refractory CD20 positive B-NHL.
- Conditions
- Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma, Non-Hodgkin's Lymphoma, B-cell Lymphoma Refractory, B-cell Lymphoma Recurrent
- Trial name
- NCT03664635
- Testing
- MB-CART20.1
- Where
- 2 sites in Germany
- Volunteers
- 10 people
- Sponsor
- Miltenyi Biomedicine GmbH
Diffuse Large B-Cell Lymphoma (DLBCL)
A Phase I/II Study of TRS005 in Combination With Cyclophosphamide, Doxorubicin, and Prednisone（T-CHP） in Previously Untreated Patients With CD20-positive DLBCL
This trial is a multicenter, open-label, single-arm, dose-escalation and dose-expansion clinical trial. The dose was increased according to the "3 + 3" rule.
- Trial name
- NCT07035379
- Testing
- TRS005, Cyclophosphamide, Doxorubicin
- Where
- China
- Volunteers
- 66 people
- Sponsor
- Zhejiang Teruisi Pharmaceutical Inc.
CD20 Positive B Cell NHL
Pharmacokinetics, Efficacy and Safety of the 304 Injection
The purpose of this study is to evaluate the pharmacokinetic of the experimental drug 304 injection compared with rituximab injection in patients with CD20 positive B-cell non-Hodgkin lymphoma who had previously achieved CR/CRu…
- Trial name
- NCT03980379
- Testing
- 304 injection, rituximab injection
- Where
- 10 sites in China
- Volunteers
- 60 people
- Sponsor
- Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.